{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:33:34Z","timestamp":1785886414141,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,26]]},"DOI":"10.7759\/cureus.52994","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T16:30:44Z","timestamp":1706286644000},"source":"Crossref","is-referenced-by-count":9,"title":["Hyperkalemia: Pharmacotherapies and Clinical Considerations"],"prefix":"10.7759","author":[{"given":"Evan  S","family":"Sinnathamby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly T","family":"Banh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William  T","family":"Barham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler D","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey  J","family":"De Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent  G","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hyperkalemia","volume":"73","author":"Hollander-Rodriguez JC","year":"2006","unstructured":"Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006, 73:283-90.","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/ajem.2002.32630","article-title":"The prominent T wave: electrocardiographic differential diagnosis","volume":"20","author":"Somers MP","year":"2002","unstructured":"Somers MP, Brady WJ, Perron AD, Mattu A. The prominent T wave: electrocardiographic differential diagnosis. Am J Emerg Med. 2002, 20:243-51. 10.1053\/ajem.2002.32630","journal-title":"Am J Emerg Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/12-088","article-title":"ECG diagnosis: hyperkalemia","volume":"17","author":"Levis JT","year":"2013","unstructured":"Levis JT. ECG diagnosis: hyperkalemia. Perm J. 2013, 17:69. 10.7812\/TPP\/12-088","journal-title":"Perm J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1699-3","article-title":"Pathogenesis, diagnosis and management of hyperkalemia","volume":"26","author":"Lehnhardt A","year":"2011","unstructured":"Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011, 26:377-84. 10.1007\/s00467-010-1699-3","journal-title":"Pediatr Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2016.01.003","article-title":"Electrophysiological and clinical consequences of\u00a0hyperkalemia","volume":"6","author":"Campese VM","year":"2016","unstructured":"Campese VM, Adenuga G. Electrophysiological and clinical consequences of\u00a0hyperkalemia. Kidney Int Suppl (2011). 2016, 6:16-9. 10.1016\/j.kisu.2016.01.003","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter RW","year":"2019","unstructured":"Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019, 34:iii2-iii11. 10.1093\/ndt\/gfz206","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.040","article-title":"Management of hyperkalemia: an update for the internist","volume":"128","author":"Kovesdy CP","year":"2015","unstructured":"Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med. 2015, 128:1281-7. 10.1016\/j.amjmed.2015.05.040","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer BF","year":"2021","unstructured":"Palmer BF, Carrero JJ, Clegg DJ, et al.. Clinical management of hyperkalemia. Mayo Clin Proc. 2021, 96:744-62. 10.1016\/j.mayocp.2020.06.014","journal-title":"Mayo Clin Proc"},{"key":"ref9","article-title":"Potassium-binding agents for the clinical management of hyperkalemia","volume":"41","author":"Chaitman M","year":"2016","unstructured":"Chaitman M, Dixit D, Bridgeman MB. Potassium-binding agents for the clinical management of hyperkalemia. P T. 2016, 41:43-50.","journal-title":"P T"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.834","article-title":"The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia","volume":"6","author":"Kessler C","year":"2011","unstructured":"Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011, 6:136-40. 10.1002\/jhm.834","journal-title":"J Hosp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000585","article-title":"Lower gastrointestinal bleeding associated with sodium polystyrene sulfonate use","volume":"8","author":"Dantas E","year":"2021","unstructured":"Dantas E, Coelho M, Sequeira C, et al.. Lower gastrointestinal bleeding associated with sodium polystyrene sulfonate use. ACG Case Rep J. 2021, 8:e00585. 10.14309\/crj.0000000000000585","journal-title":"ACG Case Rep J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000458856.92020.1e","article-title":"Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate","volume":"28","author":"Nguyen T","year":"2015","unstructured":"Nguyen T, Ondrik D, Zhufyak O, To W, He S. Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate. JAAPA. 2015, 28:41-5. 10.1097\/01.JAA.0000458856.92020.1e","journal-title":"JAAPA"},{"key":"ref13","article-title":"Evaluation of single dose sodium polystyrene sulfonate for management of hyperkalemia and its effect on other serum electrolytes","volume":"69","author":"Khatri SA","year":"2019","unstructured":"Khatri SA, Athar A, Khan A. Evaluation of single dose sodium polystyrene sulfonate for management of hyperkalemia and its effect on other serum electrolytes. Pak Armed Forces Med J. 2019, 69:37-42.","journal-title":"Pak Armed Forces Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage L","year":"2015","unstructured":"Lepage L, Dufour AC, Doiron J, et al.. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015, 10:2136-42. 10.2215\/CJN.03640415","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.12.043","article-title":"Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department","volume":"65","author":"Hasara S","year":"2023","unstructured":"Hasara S, Dubey J, Amatea J, Finnigan N. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department. Am J Emerg Med. 2023, 65:59-64. 10.1016\/j.ajem.2022.12.043","journal-title":"Am J Emerg Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/00185787211037552","article-title":"Comparison of patiromer to sodium polystyrene sulfonate in acute hyperkalemia","volume":"57","author":"Nguyen PT","year":"2022","unstructured":"Nguyen PT, Kataria VK, Sam TR, Hooper K, Mehta AN. Comparison of patiromer to sodium polystyrene sulfonate in acute hyperkalemia. Hosp Pharm. 2022, 57:359-64. 10.1177\/00185787211037552","journal-title":"Hosp Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12561","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad F","year":"2020","unstructured":"Zannad F, Hsu BG, Maeda Y, et al.. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020, 7:54-64. 10.1002\/ehf2.12561","journal-title":"ESC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0b013e3181e73f20","article-title":"Zirconium: biomedical and nephrological applications","volume":"56","author":"Lee DB","year":"2010","unstructured":"Lee DB, Roberts M, Bluchel CG, Odell RA. Zirconium: biomedical and nephrological applications. ASAIO J. 2010, 56:550-6. 10.1097\/MAT.0b013e3181e73f20","journal-title":"ASAIO J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros F","year":"2014","unstructured":"Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014, 9:e114686. 10.1371\/journal.pone.0114686","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker SD","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, et al.. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015, 17:1050-6. 10.1002\/ejhf.300","journal-title":"Eur J Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham DK","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al.. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015, 372:222-31. 10.1056\/NEJMoa1411487","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02569-7","article-title":"Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE","volume":"23","author":"Fishbane S","year":"2022","unstructured":"Fishbane S, Ford M, Fukagawa M, et al.. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE. BMC Nephrol. 2022, 23:59. 10.1186\/s12882-021-02569-7","journal-title":"BMC Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz BS","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, et al.. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019, 14:798-809. 10.2215\/CJN.12651018","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa241","article-title":"Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?","volume":"36","author":"Wesson DE","year":"2021","unstructured":"Wesson DE. Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?. Nephrol Dial Transplant. 2021, 36:756-60. 10.1093\/ndt\/gfaa241","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa158","article-title":"Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials","volume":"36","author":"Roger SD","year":"2021","unstructured":"Roger SD, Spinowitz BS, Lerma EV, et al.. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials. Nephrol Dial Transplant. 2021, 36:871-83. 10.1093\/ndt\/gfaa158","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash SR","year":"2015","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015, 88:404-11. 10.1038\/ki.2014.382","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000523911","article-title":"Effect of sodium zirconium cyclosilicate on serum potassium and bicarbonate in patients with hyperkalemia and metabolic acidosis associated with chronic kidney disease: rationale and design of the NEUTRALIZE study","volume":"146","author":"Ash SR","year":"2022","unstructured":"Ash SR, Batlle D, Kendrick J, et al.. Effect of sodium zirconium cyclosilicate on serum potassium and bicarbonate in patients with hyperkalemia and metabolic acidosis associated with chronic kidney disease: rationale and design of the NEUTRALIZE study. Nephron Clin Pract. 2022, 146:599-609. 10.1159\/000523911","journal-title":"Nephron Clin Pract"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel Z","year":"2013","unstructured":"Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013, 126:264.e9-24. 10.1016\/j.amjmed.2012.08.016","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02439-2","article-title":"The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure","volume":"22","author":"Murphy D","year":"2021","unstructured":"Murphy D, Ster IC, Kaski JC, Anderson L, Banerjee D. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure. BMC Nephrol. 2021, 22:254. 10.1186\/s12882-021-02439-2","journal-title":"BMC Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1906","article-title":"Systematic review and meta\u2010analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia","volume":"37","author":"Meaney CJ","year":"2017","unstructured":"Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta\u2010analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy. 2017, 37:401-11. 10.1002\/phar.1906","journal-title":"Pharmacotherapy"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100635","article-title":"Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis","volume":"95","author":"Shrestha DB","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, et al.. Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2021, 95:100635. 10.1016\/j.curtheres.2021.100635","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07134-2","article-title":"Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis","volume":"35","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Xu R, Wang F, et al.. Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021, 35:1057-66. 10.1007\/s10557-020-07134-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref33","unstructured":"Hyperkalemia treatment. LOKELMA for oral suspension. (2023). Accessed: February 14, 2023: https:\/\/www.lokelma-hcp.com."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5104-328","article-title":"Patiromer","volume":"51","author":"Cada DJ","year":"2016","unstructured":"Cada DJ, Dang J, Baker DE. Patiromer. Hosp Pharm. 2016, 51:328-36. 10.1310\/hpj5104-328","journal-title":"Hosp Pharm"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt B","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011, 32:820-8. 10.1093\/eurheartj\/ehq502","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir MR","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al.. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015, 372:211-21. 10.1056\/NEJMoa1410853","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris GL","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, et al.. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015, 314:151-61. 10.1001\/jama.2015.7446","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226844","article-title":"Hyperkalemia treatment modalities: a descriptive observational study focused on medication and healthcare resource utilization","volume":"15","author":"Desai NR","year":"2020","unstructured":"Desai NR, Rowan CG, Alvarez PJ, Fogli J, Toto RD. Hyperkalemia treatment modalities: a descriptive observational study focused on medication and healthcare resource utilization. PLoS One. 2020, 15:e0226844. 10.1371\/journal.pone.0226844","journal-title":"PLoS One"},{"key":"ref39","unstructured":"Valtessa (patiromer). (2023). Accessed. February 14, 2023: https:\/\/veltassa.com\/hcp\/."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia","volume":"88","author":"Bushinsky DA","year":"2015","unstructured":"Bushinsky DA, Williams GH, Pitt B, et al.. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015, 88:1427-33. 10.1038\/ki.2015.270","journal-title":"Kidney Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00254-7","article-title":"Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program","volume":"8","author":"Rossignol P","year":"2021","unstructured":"Rossignol P, David L, Chan C, Conrad A, Weir MR. Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program. Drugs Real World Outcomes. 2021, 8:315-23. 10.1007\/s40801-021-00254-7","journal-title":"Drugs Real World Outcomes"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1106935","article-title":"Patiromer: a clinical review","volume":"32","author":"Montaperto AG","year":"2016","unstructured":"Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Patiromer: a clinical review. Curr Med Res Opin. 2016, 32:155-64. 10.1185\/03007995.2015.1106935","journal-title":"Curr Med Res Opin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/216540-hyperkalemia-pharmacotherapies-and-clinical-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:22Z","timestamp":1707509662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/216540-hyperkalemia-pharmacotherapies-and-clinical-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.52994","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}